The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Treating patients with poor-risk cytogenetics with venetoclax and HMAs
Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, discusses outcomes of treatment-naïve patients with acute myeloid leukemia (AML) with poor-risk cytogenetics or poor-karyotype treated with venetoclax and hypomethylating agents (HMAs). Data from a Phase III (NCT02993523) and Phase Ib trial (NCT02203773) were analyzed, where patients received venetoclax with azacitidine and venetoclax with decitabine respectively. Having a poor-risk cytogenetics profile was not found to affect outcomes, whereas the presence of TP53 mutations worsened outcomes. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
